| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_bddd83b0d4337e850c8a5e184ed0ec20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_396ebf23018b0c0ecf1fb4ae221150e5
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_c5073a0063d6be9e25c14d2af0a1ee89
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b49c450dd5d7f4fc427a6ebcf59640a0
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_112550b1b7fdad030493300629d55245
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_32ee382bd6c788ee4cd78be8cba30d24 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P27-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-17
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-14 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P27-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-17 |
| filingDate |
2016-08-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7432a1826cc3f257700c206f287b7cab
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5e7cb4461fab12d8f8d0df9a25dde933
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1b53602cf7109f89592913f38f3010ee
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_acc613d3efc748a3f3af157e1ddc8433
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f9f7cdd64adda6283dd6cb5e90a27cac |
| publicationDate |
2017-02-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2017021560-A1 |
| titleOfInvention |
Use of hydroxycarbamide for preventing retinal nonperfusion |
| abstract |
The present invention relates to the use of hydroxycarbamide (HC) for reducing and/or delaying the extension of capillary nonperfusion, a cause of irreparable visual impairment in patients suffering from central retinal vein occlusion (CRVO). This is the first systemic treatment which makes it possible to reduce retinal ischemic complications in patients in whom (CRVO) has been recently diagnosed and is consequently in a rapidly progressive phase. Given the low toxicity of HC evaluated on a large scale in children and adults in the context of other diseases for decades, the results of the present study open up a new therapeutic approach in the treatment of CRVO. |
| priorityDate |
2015-08-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |